Loading
A phase 2 trial of Fostamatinib in Head and neck squamous cell carcinoma and Pheochromocytoma and paraganglioma, run by National Cancer Institute (NCI), completed.
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H.. is a phase 2 interventional study registered as NCT00923481 by National Cancer Institute (NCI), with 37 participants recorded, started 2009-04 and reaching its primary completion in 2009-04. Interventions recorded: Fostamatinib disodium. Conditions recorded: Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell.
Linked to the drug Fostamatinib because the registry names it among its interventions and Head and neck squamous cell carcinoma and Pheochromocytoma and paraganglioma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fostamatinib and the tag pipeline.
Shares Fostamatinib and the tag pipeline.
Shares Pheochromocytoma and paraganglioma (PPGL) and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Pheochromocytoma and paraganglioma (PPGL) and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/